About Theragnostics
Theragnostics is a private clinical-stage pharmaceutical company developing precision oncology products for diagnostic medical imaging and targeted radionuclide therapy. The Company has completed several proof-of-concept phase I and II clinical trials for several radionuclide diagnostics and targeted therapies.
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
About NephroScan
Following intravenous administration, the radiopharmaceutical agent Tc-99m dimercaptosuccinic acid (Tc-99m DMSA) principally binds to the cortical regions of the kidneys. Its biodistribution makes it a logical imaging agent for renal scintigraphy. It is imaged by different methods such as planar and pinhole imaging and SPECT. Tc-99m DMSA imaging during acute renal infection has been used to identify patients that are at risk for later development of permanent sequalae such as parenchymal scarring, hypertension, and even chronic renal failure. Tc-99m DMSA imaging can also be used for the determination of split renal function, kidney shape, size, position, and homogeneity1.
About ROTOP Pharmaka GmbH
ROTOP Pharmaka is a leading radiopharmaceutical company with over 20 years of experience that produces cGMP compliant cold kits and radiopharmaceuticals in Germany and supplies to over 30+ countries. Apart from development, manufacturing, and registration of radiopharmaceuticals, ROTOP offers a broad range of CDMO Services. For more information visit: www.rotop-pharmaka.de.
About GE Healthcare
GE Healthcare is the $17.7 billion healthcare business of GE (NYSE: GE). As a leading global medical technology, pharmaceutical diagnostics and digital solutions innovator, GE Healthcare enables clinicians to make faster, more informed decisions through intelligent devices, data analytics, applications and services, supported by its Edison intelligence platform. With over 100 years of healthcare industry experience and around 47,000 employees globally, the company operates at the center of an ecosystem working toward precision health, digitizing healthcare, helping drive productivity and improve outcomes for patients, providers, health systems and researchers around the world.
SOURCE Theragnostics
Back to HCB News
